作者
Hiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al Khatib, Patrick Tang, Mohammad R Hasan, Joel A Malek, Peter Coyle, Houssein H Ayoub, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul Rahim, Gheyath K Nasrallah, Mohamed Ghaith Al Kuwari, Hamad Eid Al Romaihi, Mohamed H Al-Thani, Abdullatif Al Khal, Adeel A Butt, Roberto Bertollini, Laith J Abu-Raddad
发表日期
2021/9
期刊
Nature medicine
卷号
27
期号
9
页码范围
1614-1621
出版商
Nature Publishing Group US
简介
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days …
学术搜索中的文章
H Chemaitelly, HM Yassine, FM Benslimane… - Nature medicine, 2021